TuHURA ने मर्केल सेल कार्सिनोमा में IFx-2.0 + Keytruda का चरण 3 परीक्षण शुरू किया

स्रोत का अंश

EX-99.1 2 d73851dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Business Except as otherwise specified or indicated by the context, references to “we,” “us,” “our” or the “company” are to TuHURA Biosciences, Inc. and its wholly owned subsidiaries. Overview We are a clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. Our proprietary Immune FxTM technology platform, or IFx, is an innate immune agonist technology designed to “trick” the body’s immune system to attack tumor cells by making tumor cells look like bacteria. Our lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. I

SEC 8-K